Last updated: February 26, 2026
What is the drug associated with NDC 70710-1242?
The National Drug Code (NDC) 70710-1242 corresponds to Xyrem (sodium oxybate). It is a central nervous system depressant approved by the FDA for the treatment of narcolepsy with cataplexy and idiopathic hypersomnia.
What is the current market landscape?
Regulatory Status and Approval
- FDA approval granted in 2002 for narcolepsy with cataplexy.
- Expanded approval in 2019 for idiopathic hypersomnia.
- Schedule III controlled substance due to abuse potential.
Market size and growth
- Global narcolepsy drug market was valued at approximately USD 500 million in 2022.
- Projected CAGR (2023–2028) of 6.5%, reflecting increasing diagnosis rates and evolving treatment options, including sodium oxybate.
Competitive positioning
- Market leader in treating narcolepsy with cataplexy.
- Main competitors include Solriamfetol (Sunosi), Pitolisant (Wakix), and newer agents under development (e.g., JZP-258, a lower-sodium formulation of sodium oxybate).
Key market drivers
- Growing awareness and diagnosis.
- Expanded indication for hypersomnia.
- Insurance coverage enhancements, despite high drug costs.
- Limited number of approved alternatives, reinforcing market dominance.
Pricing and reimbursement landscape
- Average wholesale price (AWP): approximately USD 1,200–1,500 per 30 mL bottle.
- Prescribed dosage: 4.5–9 g nightly, split into two doses.
- High-cost due to Schedule III classification, with coverage typically provided via commercial insurance, Medicaid, or Medicare.
Price projections analysis
| Year |
Estimated Average Price per 30 mL |
Key Factors Affecting Price |
| 2023 |
USD 1,200–1,500 |
No significant change; market stability, patent exclusivity persists. |
| 2024 |
USD 1,250–1,550 |
Slight increase expected due to inflation and manufacturing costs. |
| 2025 |
USD 1,300–1,600 |
Marginal increase; potential for formulary negotiations. |
| 2026 |
USD 1,350–1,650 |
Price stabilization as market matures; entry of biosimilar-like formulations unlikely. |
| 2027 |
USD 1,400–1,700 |
Possible slight increase; patent exclusivity may near expiry in select regions. |
Factors influencing future pricing
-
Patent expirations: The core patent expired in 2019; however, extended exclusivities or additional formulations (e.g., lower sodium versions) could sustain pricing.
-
Market competition: Introduction of generic sodium oxybate formulations could pressure prices downward starting 2024–2025 in select markets, especially outside the U.S.
-
Regulatory and reimbursement policies: Cost containment measures could moderate or reduce prices through formulary constraints or increased generic market penetration.
-
Manufacturing costs: Elevated due to safety protocols for Schedule III substances, possibly constraining price decreases.
Conclusion
While the core patent for sodium oxybate expired in 2019, market dominance persists through regulatory barriers and formulary placements, maintaining high prices. The market is expected to remain relatively stable through 2026, with modest increases aligned with inflation and operational costs. Entry of generic competitors is likely around 2024–2025, which could lead to significant downward pressure on drug prices outside the United States.
Key Takeaways
- NDC 70710-1242 (Xyrem) maintains high prices driven by limited competition and regulatory hurdles.
- Market growth is driven by increasing diagnosis and expanded indications.
- Price projections suggest modest increases until generics influence the market around 2024–2025.
- Competitive landscape includes newer agents and formulations attempting to carve market segments.
- Price sensitivity will depend heavily on regulatory decisions, patent status, and market entry by generics.
FAQs
Q1: When do generic sodium oxybate formulations potentially enter the market?
A1: Likely around 2024–2025, contingent on patent expirations and regulatory approvals.
Q2: How does insurance coverage impact patient access to Xyrem?
A2: Insurance typically covers most costs, but high drug prices can limit access without coverage; patient assistance programs are common.
Q3: Are there alternative treatments with similar efficacy?
A3: Yes. Solriamfetol and Pitolisant offer different mechanisms but target similar symptoms; however, sodium oxybate remains preferred for certain cases.
Q4: What innovations could influence the drug’s pricing?
A4: New formulations (e.g., lower-sodium versions), biosimilars, and regulatory changes could impact pricing dynamics.
Q5: How does Schedule III classification affect market dynamics?
A5: It imposes restrictions on prescribing, manufacturing, and dispensing, which can influence supply stability and pricing.
References
[1] U.S. Food and Drug Administration. (2022). Xyrem (sodium oxybate) official label.
[2] MarketResearch.com. (2023). Global narcolepsy therapeutics market forecast.
[3] IQVIA. (2023). 2022 Pharmaceutical Pricing and Reimbursement Trends Report.
[4] FDA. (2019). Expanded approval for lower sodium oxybate formulations.
[5] Statista. (2023). Overview of Schedule III drugs in the U.S.
